Published in:
01-03-2016 | Editorial Commentary
68Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging
Authors:
Felix M. Mottaghy, Florian F. Behrendt, Frederik A. Verburg
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 3/2016
Login to get access
Excerpt
Nuclear medicine is currently taking great steps towards gaining a much more prominent role in the care of patients with prostate cancer. Prostate-specific membrane antigen (PSMA) has been a theranostic target of interest in prostate cancer for over two decades and
111In/
177Lu antibody-based imaging and therapy have been studied extensively but without gaining widespread clinical acceptance [
1‐
3]. However, since the introduction of novel functional ligands for PSMA such as Glu-urea-Lys-(Ahx)-[
68Ga(HBED-CC)] (
68Ga-PSMA) [
4,
5], PSMA-DKFZ-617 [
6‐
8] or EuK-Subkff-
68Ga
-DOTAGA [
9], the number of publications on specifically PSMA-targeted imaging has increased exponentially. This shows the extraordinary potential of this approach as a blockbuster modality for nuclear medicine. …